AI model may personalize liver cancer care after surgery
NCT ID NCT07562763
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor the patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- transcatheter arterial chemoembolization (TACE)
- What this could lead to
- If successful, this could help doctors personalize treatment decisions for liver cancer patients after surgery, potentially improving outcomes.
- What could go wrong
- This is a retrospective analysis, not a controlled trial, so results may not apply to all patients. The model needs further validation before clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of USTC
Hefei, Anhu, 23000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can an immune booster after lung cancer surgery keep the disease at bay?
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a machine learning model beat standard tools in spotting sepsis early?
- AI-Powered surveillance may outsmart liver cancer recurrence